Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.

You may also be interested in...



Bavarian Nordic, GSK To Produce Imvamune For Smallpox Vaccine Stockpile

The companies will collaborate on manufacturing the modified vaccinia Ankara-Bavarian Nordic vaccine for any future HHS contracts. Under the deal, GSK will also market Imvamune in the Americas, Japan and parts of the EU.

Bavarian Nordic, GSK To Produce Imvamune For Smallpox Vaccine Stockpile

The companies will collaborate on manufacturing the modified vaccinia Ankara-Bavarian Nordic vaccine for any future HHS contracts. Under the deal, GSK will also market Imvamune in the Americas, Japan and parts of the EU.

Mixed Smallpox Vaccine Stockpile Could Complicate Mass Vaccination, Bavarian Nordic Says

Smallpox vaccine candidate Imvamune has not demonstrated the potential for serious adverse events associated with Wyeth's Dryvax or Acambis/Baxter's ACAM-2000, VP-R&D Paul Chaplin, PhD, says in interview with "The Blue Sheet."

Related Content

Topics

UsernamePublicRestriction

Register

PS059298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel